CHF85.34
0.37% yesterday
SIX Swiss Exchange, Nov 15, 05:31 pm CET
ISIN
CH1335392721
Symbol
GALD
Sector
Industry

Galderma Target price 2024 - Analyst rating & recommendation

Galderma Classifications & Recommendation:

Buy
83%
Hold
17%

Galderma Price Target

Target Price CHF90.50
Price CHF85.34
Potential
Number of Estimates 11
11 Analysts have issued a price target Galderma 2025 . The average Galderma target price is CHF90.50. This is higher than the current stock price. The highest price target is
CHF105.51 23.63%
register free of charge
, the lowest is .
A rating was issued by 12 analysts: 10 Analysts recommend Galderma to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Galderma stock has an average upside potential 2025 of . Most analysts recommend the Galderma stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Revenue Billion CHF 3.67 3.85
2.14% 5.09%
EBITDA Margin 20.89% 22.73%
14.87% 8.83%
Net Margin -1.42% 4.44%
46.15% 411.60%

11 Analysts have issued a sales forecast Galderma 2024 . The average Galderma sales estimate is

CHF3.9b
Unlock
. This is
1.46% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF3.9b 2.43%
Unlock
, the lowest is
CHF3.8b 0.62%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 CHF3.7b 2.14%
2024
CHF3.9b 5.09%
Unlock
2025
CHF4.3b 11.85%
Unlock
2026
CHF4.9b 14.35%
Unlock
2027
CHF6.0b 21.99%
Unlock
2028
CHF6.7b 12.21%
Unlock

11 Analysts have issued an Galderma EBITDA forecast 2024. The average Galderma EBITDA estimate is

CHF876m
Unlock
. This is
12.26% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF895m 14.65%
Unlock
, the lowest is
CHF804m 3.02%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 CHF766m 17.32%
2024
CHF876m 14.38%
Unlock
2025
CHF994m 13.42%
Unlock
2026
CHF1.2b 24.57%
Unlock
2027
CHF1.6b 31.05%
Unlock
2028
CHF2.0b 22.09%
Unlock

EBITDA Margin

2023 20.89% 14.87%
2024
22.73% 8.83%
Unlock
2025
23.05% 1.41%
Unlock
2026
25.11% 8.94%
Unlock
2027
26.98% 7.45%
Unlock
2028
29.35% 8.78%
Unlock

8 Galderma Analysts have issued a net profit forecast 2024. The average Galderma net profit estimate is

CHF171m
Unlock
. This is
1,541.26% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF218m 1,933.23%
Unlock
, the lowest is
CHF131m 1,206.71%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 CHF-52.3m 45.00%
2024
CHF171m 427.56%
Unlock
2025
CHF414m 141.96%
Unlock
2026
CHF648m 56.38%
Unlock
2027
CHF997m 53.88%
Unlock
2028
CHF1.3b 32.00%
Unlock

Net Margin

2023 -1.42% 46.15%
2024
4.44% 411.60%
Unlock
2025
9.61% 116.44%
Unlock
2026
13.14% 36.73%
Unlock
2027
16.57% 26.10%
Unlock
2028
19.50% 17.68%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share CHF -0.22 0.72
45.00% 427.27%
P/E 118.43
EV/Sales 5.86

8 Analysts have issued a Galderma forecast for earnings per share. The average Galderma <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

CHF0.72
Unlock
. This is
1,540.00% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
CHF0.92 1,940.00%
Unlock
, the lowest is
CHF0.55 1,200.00%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 CHF-0.22 45.00%
2024
CHF0.72 427.27%
Unlock
2025
CHF1.74 141.67%
Unlock
2026
CHF2.73 56.90%
Unlock
2027
CHF4.20 53.85%
Unlock
2028
CHF5.54 31.90%
Unlock

P/E ratio

Current
2024
118.43 107.23%
Unlock
2025
48.94 58.68%
Unlock
2026
31.30 36.04%
Unlock
2027
20.34 35.02%
Unlock
2028
15.41 24.24%
Unlock

Based on analysts' sales estimates for 2024, the Galderma stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.94
2024
5.86 1.41%
Unlock
2025
5.24 10.59%
Unlock
2026
4.58 12.55%
Unlock
2027
3.75 18.02%
Unlock
2028
3.35 10.88%
Unlock

P/S ratio

Current
2024
5.26 1.44%
Unlock
2025
4.70 10.59%
Unlock
2026
4.11 12.55%
Unlock
2027
3.37 18.02%
Unlock
2028
3.00 10.88%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today